The Cochrane Verdict on Cannabis for Nerve Pain: Modest Benefit, Significant Side Effects
The updated Cochrane Review found cannabis-based medicines provide modest pain relief for chronic neuropathic pain—but only a minority of patients achieve meaningful benefit, and side effects are common.
Quick Facts
What This Study Found
This is the definitive evidence synthesis on cannabis for neuropathic pain—an updated Cochrane Review (originally published 2018) that applied the most rigorous inclusion criteria available: only randomized, double-blind trials lasting at least two weeks.
The critical outcome was the proportion of patients achieving at least 50% pain relief—the threshold considered clinically meaningful. The review found that cannabis-based medicines (herbal, plant-based, and synthetic) did help some patients reach this threshold compared to placebo, but the effect was modest—only a minority benefited substantially.
A Patient Global Impression of Change (much or very much improved) was also more common with cannabis than placebo, again with modest effect sizes.
The other side of the equation: adverse events were significantly more common with cannabis. Side effects limited the clinical utility of the treatments, and the balance between benefit and harm was a central concern.
The review included herbal cannabis, plant-derived products (like nabiximols/Sativex), and synthetic cannabinoids (like nabilone and dronabinol), recognizing these as distinct pharmacological approaches that may have different benefit-harm profiles.
The evidence quality was mixed—some outcomes had moderate-quality evidence while others were rated lower, reflecting the limitations of the underlying trials.
Key Numbers
Population prevalence of neuropathic pain: 6–10%. Searches through January 2025. Included only double-blind RCTs ≥2 weeks. Some patients achieved ≥50% pain relief. Cannabis had more adverse events than placebo. Multiple cannabis types assessed (herbal, plant-derived, synthetic).
How They Did This
Cochrane systematic review (update of 2018 review). Searched CENTRAL, MEDLINE, Embase, and trial registries through January 2025. Included randomized, double-blind controlled trials of cannabis-based medicines vs. placebo or active treatment for chronic neuropathic pain in adults, with treatment ≥2 weeks. Critical outcomes: ≥50% pain relief, PGIC, adverse events.
Why This Research Matters
This is the gold standard of evidence synthesis for a clinical question that millions of people face. The answer—modest benefit for some, significant side effects for many—is more nuanced than either 'cannabis works for pain' or 'cannabis doesn't work for pain.' For the 6–10% of the population with neuropathic pain, this review provides the most reliable evidence to date for making treatment decisions.
The Bigger Picture
This Cochrane Review provides essential context for other pain findings in the database. RTHC-00221's 91.5% neuropathic pain response in an uncontrolled cohort looks very different next to this review's modest RCT results—the gap between real-world uncontrolled data and rigorous controlled trials is enormous. RTHC-00182's null result for CBD in osteoarthritis and RTHC-00158's mixed cancer results are consistent with the pattern: cannabis's analgesic effects are real but modest, condition-specific, and accompanied by meaningful side effects.
What This Study Doesn't Tell Us
The underlying trials varied in cannabis type, dose, duration, and population. Some trials were small. The 2-week minimum duration excludes very short studies but may still not capture long-term effects. Neuropathic pain is heterogeneous—some subtypes may respond better than others. The distinction between different cannabis products within the review may not be granular enough.
Questions This Raises
- ?Which specific neuropathic pain subtypes respond best?
- ?Would longer treatment durations show sustained or diminishing benefit?
- ?Could personalized approaches (pharmacogenomics, pain subtyping) identify the minority who benefit substantially?
Trust & Context
- Key Stat:
- Evidence Grade:
- Cochrane systematic review of double-blind RCTs—the highest level of evidence synthesis, though limited by the quality of the underlying trials.
- Study Age:
- Published in 2026, updating the 2018 Cochrane Review with searches through January 2025.
- Original Title:
- Cannabis-based medicines for chronic neuropathic pain in adults.
- Published In:
- The Cochrane database of systematic reviews, 1(1), CD012182 (2026) — The Cochrane Database of Systematic Reviews is a highly respected source for evidence-based healthcare information.
- Authors:
- Ateş, Gülay, Welsch, Patrick(3), Klose, Petra(3), Phillips, Tudor, Lambers, Britta, Häuser, Winfried, Radbruch, Lukas
- Database ID:
- RTHC-08093
Evidence Hierarchy
Analyzes all available research on a topic using a structured method.
What do these levels mean? →Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
- cannabis-and-fibromyalgia-evidence-dosing
- cannabis-and-carpal-tunnel-nerve-pain
- cannabis-and-migraines-prevention-treatment
Cite This Study
https://rethinkthc.com/research/RTHC-08093APA
Ateş, Gülay; Welsch, Patrick; Klose, Petra; Phillips, Tudor; Lambers, Britta; Häuser, Winfried; Radbruch, Lukas. (2026). Cannabis-based medicines for chronic neuropathic pain in adults.. The Cochrane database of systematic reviews, 1(1), CD012182. https://doi.org/10.1002/14651858.CD012182.pub3
MLA
Ateş, Gülay, et al. "Cannabis-based medicines for chronic neuropathic pain in adults.." The Cochrane database of systematic reviews, 2026. https://doi.org/10.1002/14651858.CD012182.pub3
RethinkTHC
RethinkTHC Research Database. "Cannabis-based medicines for chronic neuropathic pain in adu..." RTHC-08093. Retrieved from https://rethinkthc.com/research/ates-2026-cannabisbased-medicines-for-chronic
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.